Immunophenotyping results from the hospital laboratory
| . | P1 . | P2 . | P3 . | Standards . | ||||
|---|---|---|---|---|---|---|---|---|
| Sex | Male | Female | Male | |||||
| Age (at initial evaluation; mo) | 11 | 48 | 24 | |||||
| Serum IgG levels (g/liter) | NA | 2.27 | 2.50 | 7–14 | ||||
| Serum IgA levels (g/liter) | NA | 0.26 | 0.22 | 0.90–4 | ||||
| Serum IgM levels (g/liter) | NA | 0.43 | 0.18 | 0.50–2.50 | ||||
| Age (at evaluation; yr) | 35 | 31 | 28 | |||||
| Serum IgE levels (kUI/liter) | <2 | <5 | <5 | <100 | ||||
| P1 | P2 | P3 | Standards | |||||
| Age (at evaluation; yr) | 53 | 57 | 60 | 31 | 21 | 26 | 28 | |
| T lymphocytes | ||||||||
| CD3+ (/µl) | 590 | 344 | 819 | 903 | 4,421 | 1,157 | 1,928 | 1,008–1,647 |
| CD3+ CD4+ (/µl) | 181 | 116 | 284 | 457 | 1,350 | 450 | 597 | 480–1,320 |
| Activated CD4+ (HLA-DR+/CD3+CD4+; %) | 18.3 | NA | NA | NA | 12 | 11.1 | NA | 5–12 |
| Naïve CD4+ (CD45RA+CCR7+/CD3+CD4+; %) | 7.5 | 8.8 | 4.6 | 11.9 | 10.7 | 15.0 | 10.8 | 26–54 |
| Memory CD4+ (CD45ROb+/CD3+CD4+; %) | 84.7 | NA | NA | NA | 54.5 | 72.7 | NA | 40–61 |
| Central memory CD4+ (CD45RA−CCR7+/CD3+CD4+; %) | 43.8 | 59.2 | 64.2 | 57.4 | 20 | 35.5 | 24.3 | 28–51 |
| Mem effector CD4+ (CD45RA−CCR7−/CD3+CD4+; %) | 38.5 | 25 | 26.3 | 18.2 | 32.5 | 39.5 | 42.8 | 7.8–23.2 |
| Terminal effector CD4+ (CD45RA+CCR7−/CD3+CD4+; %) | 10.3 | 6.9 | 4.9 | 12.6 | 36.8 | 10.1 | 22.2 | 0–2.9 |
| CD3+ CD8+ (/µl) | 404 | 225 | 539 | 446 | 3,074 | 691 | 1,290 | 192–720 |
| Activated CD8+ (HLA-DR+/CD3+CD8+; %) | 32.8 | NA | NA | NA | 19.1 | 19.6 | NA | 9–33 |
| Naïve CD8+ (CD45RA+CCR7+/CD3+CD8+; %) | 1.2 | 1.7 | 1.9 | 5.7 | 3.0 | 6.7 | 3.3 | 24.2–53.6 |
| Memory CD8+ (CD45ROb+/CD3+CD8+; %) | 54.6 | NA | NA | NA | 63.4 | 73.9 | NA | 21–48 |
| Central memory CD8+ (CD45RA−CCR7+/CD3+CD8+; %) | 4.3 | 4.9 | 7.7 | 6.5 | 1.2 | 3.8 | 2.6 | 5.1–19.6 |
| Mem effector CD8+ (CD45RA−CCR7−/CD3+CD8+; %) | 37.7 | 34.1 | 39.1 | 30.1 | 58.6 | 73.0 | 73.5 | 16.4–32.6 |
| Terminal effector CD8+ (CD45RA+CCR7−/CD3+CD8+; %) | 56.8 | 59.4 | 51.3 | 57.8 | 37.3 | 16.5 | 20.5 | 5.2–37.4 |
| NK cells | ||||||||
| CD3−CD16+CD56+ (/µl) | 19 | 18 | 44 | 94 | NA | 82 | 69 | 56–400 |
| B lymphocytes | ||||||||
| CD19+ (/µl) | 260 | 30 | 83 | 84 | 239 | 123 | 127 | 67–270 |
| Naïve B cells (CD27−IgD+/CD19+; %) | 88 | 85.2 | 70.7 | 64.2 | 41.4 | 42.6 | 50.8 | 51–77 |
| Memory B cells (CD27+/CD19+; %) | 12 | 10.9 | 16.7 | 32.3 | 52 | 49.3 | 41.1 | 23–49 |
| Un-switched mem (CD27+IgD+/CD19+; %) | 6.4 | 5.1 | 9.5 | 15.4 | 45.5 | 32.5 | 31.3 | 3–40 |
| Switched mem (CD27+IgD−/CD19+; %) | 5 | 6.1 | 6.8 | 16.5 | 7.7 | 16.6 | 11.1 | 4.4–20.5 |
| CD21low B cells (CD19+CD21low; %) | 2.5 | 4.5 | 11.1 | 32.9 | 24.4 | 38.7 | 50.4 | <5 |
| . | P1 . | P2 . | P3 . | Standards . | ||||
|---|---|---|---|---|---|---|---|---|
| Sex | Male | Female | Male | |||||
| Age (at initial evaluation; mo) | 11 | 48 | 24 | |||||
| Serum IgG levels (g/liter) | NA | 2.27 | 2.50 | 7–14 | ||||
| Serum IgA levels (g/liter) | NA | 0.26 | 0.22 | 0.90–4 | ||||
| Serum IgM levels (g/liter) | NA | 0.43 | 0.18 | 0.50–2.50 | ||||
| Age (at evaluation; yr) | 35 | 31 | 28 | |||||
| Serum IgE levels (kUI/liter) | <2 | <5 | <5 | <100 | ||||
| P1 | P2 | P3 | Standards | |||||
| Age (at evaluation; yr) | 53 | 57 | 60 | 31 | 21 | 26 | 28 | |
| T lymphocytes | ||||||||
| CD3+ (/µl) | 590 | 344 | 819 | 903 | 4,421 | 1,157 | 1,928 | 1,008–1,647 |
| CD3+ CD4+ (/µl) | 181 | 116 | 284 | 457 | 1,350 | 450 | 597 | 480–1,320 |
| Activated CD4+ (HLA-DR+/CD3+CD4+; %) | 18.3 | NA | NA | NA | 12 | 11.1 | NA | 5–12 |
| Naïve CD4+ (CD45RA+CCR7+/CD3+CD4+; %) | 7.5 | 8.8 | 4.6 | 11.9 | 10.7 | 15.0 | 10.8 | 26–54 |
| Memory CD4+ (CD45ROb+/CD3+CD4+; %) | 84.7 | NA | NA | NA | 54.5 | 72.7 | NA | 40–61 |
| Central memory CD4+ (CD45RA−CCR7+/CD3+CD4+; %) | 43.8 | 59.2 | 64.2 | 57.4 | 20 | 35.5 | 24.3 | 28–51 |
| Mem effector CD4+ (CD45RA−CCR7−/CD3+CD4+; %) | 38.5 | 25 | 26.3 | 18.2 | 32.5 | 39.5 | 42.8 | 7.8–23.2 |
| Terminal effector CD4+ (CD45RA+CCR7−/CD3+CD4+; %) | 10.3 | 6.9 | 4.9 | 12.6 | 36.8 | 10.1 | 22.2 | 0–2.9 |
| CD3+ CD8+ (/µl) | 404 | 225 | 539 | 446 | 3,074 | 691 | 1,290 | 192–720 |
| Activated CD8+ (HLA-DR+/CD3+CD8+; %) | 32.8 | NA | NA | NA | 19.1 | 19.6 | NA | 9–33 |
| Naïve CD8+ (CD45RA+CCR7+/CD3+CD8+; %) | 1.2 | 1.7 | 1.9 | 5.7 | 3.0 | 6.7 | 3.3 | 24.2–53.6 |
| Memory CD8+ (CD45ROb+/CD3+CD8+; %) | 54.6 | NA | NA | NA | 63.4 | 73.9 | NA | 21–48 |
| Central memory CD8+ (CD45RA−CCR7+/CD3+CD8+; %) | 4.3 | 4.9 | 7.7 | 6.5 | 1.2 | 3.8 | 2.6 | 5.1–19.6 |
| Mem effector CD8+ (CD45RA−CCR7−/CD3+CD8+; %) | 37.7 | 34.1 | 39.1 | 30.1 | 58.6 | 73.0 | 73.5 | 16.4–32.6 |
| Terminal effector CD8+ (CD45RA+CCR7−/CD3+CD8+; %) | 56.8 | 59.4 | 51.3 | 57.8 | 37.3 | 16.5 | 20.5 | 5.2–37.4 |
| NK cells | ||||||||
| CD3−CD16+CD56+ (/µl) | 19 | 18 | 44 | 94 | NA | 82 | 69 | 56–400 |
| B lymphocytes | ||||||||
| CD19+ (/µl) | 260 | 30 | 83 | 84 | 239 | 123 | 127 | 67–270 |
| Naïve B cells (CD27−IgD+/CD19+; %) | 88 | 85.2 | 70.7 | 64.2 | 41.4 | 42.6 | 50.8 | 51–77 |
| Memory B cells (CD27+/CD19+; %) | 12 | 10.9 | 16.7 | 32.3 | 52 | 49.3 | 41.1 | 23–49 |
| Un-switched mem (CD27+IgD+/CD19+; %) | 6.4 | 5.1 | 9.5 | 15.4 | 45.5 | 32.5 | 31.3 | 3–40 |
| Switched mem (CD27+IgD−/CD19+; %) | 5 | 6.1 | 6.8 | 16.5 | 7.7 | 16.6 | 11.1 | 4.4–20.5 |
| CD21low B cells (CD19+CD21low; %) | 2.5 | 4.5 | 11.1 | 32.9 | 24.4 | 38.7 | 50.4 | <5 |
NA: not available. Values above or below reference ranges are marked in bold.